Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture

Journal of Neural Transmission

Volumn 113, Issue 9, 2006, Pages 1095-1105

  Moldzio, R ^a   Radad, K ^a   Duvigneau, J C ^a   Kranner, B ^a   Krewenka, C ^a   Piskernik, C ^a   Rausch, W D ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cell culture; Dopamine receptor agonists; Dopamine receptor antagonists; Glutamate; Lisuride; Parkinson's disease; Sulpiride

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; LACTATE DEHYDROGENASE; LISURIDE MALEATE; NITRIC OXIDE; PROPIDIUM IODIDE; RADICAL; SULPIRIDE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DEATH; CELL DEGENERATION; CELL LOSS; CELL PROTECTION; CELL STRUCTURE; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVITY; EXPOSURE; FEMALE; MESENCEPHALON; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; CELL DEATH; CELLS, CULTURED; DOPAMINE; DOPAMINE ANTAGONISTS; ENZYME ACTIVATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FREE RADICALS; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; LACTIC ACID; LISURIDE; MESENCEPHALON; MICE; MICROSCOPY, FLUORESCENCE; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PREGNANCY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SULPIRIDE; SUPEROXIDES;

EID: 33747889995     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0394-1     Document Type: Article

References (46)

1. A Atlante P Calissano A Bobba S Giannattasio E Marra S Passarella 2001 Glutamate neurotoxicity, oxidative stress and mitochondria FEBS Lett 497 1 5
2. GC Brown A Bal-Price 2003 Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria Mol Neurobiol 27 325 355
3. W Dauer S Przedborski 2003 Parkinson's disease: mechanisms and models Neuron 39 889 909
4. AG Dervan CK Meshul M Beales GJ [tmp] McBean C Moore S Totterdell AK Snyder GE Meredith 2004 Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease Exp Neurol 190 145 156
5. A Dienel L Hertz 2001 Glucose and lactate metabolism during brain activation J Neurosci Res 66 824 838
6. DA Di Monte I Tokar JW Langston 1999 Impaired glutamate clearance as a consequence of energy failure caused by MPP+ in astrocytic cultures Toxicol Appl Pharmacol 158 296 302
7. A Doble 1999 The role of excitotoxicity in neurodegenerative disease: implications for therapy Pharmacol Ther 81 163 221
8. KL Double GM Halliday J Henderson FM Griffiths T Heinemann P Riederer M Gerlach 2003 The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration Exp Neurol 184 530 535
9. P Foley M Gerlach KL Double P Riederer 2004 Dopamine receptor agonists in the therapy of Parkinson's disease J Neural Transm 111 1375 1446
10. A Favit MA Sortino G Aleppo U Scapapnini PL Canonico 1993 Protection by dihydroergocryptine of glutamate-induced neurotoxicity Pharmacol Toxicol 73 24 28
11. CE Gavin KK Gunter TE Gunter 1999 Manganese and calcium transport in mitochondria: implications for manganese toxicity Neurotoxicology 20 445 453
12. M Gerlach K Double H Reichmann P Riederer 2003 Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease J Neural Transm (Suppl) 65 167 183
13. G Gille WD Rausch ST Hung R Moldzio A Ngyuen B Janetzky A Engfer H Reichmann 2002 Protection of dopaminergic neurons in primary culture by lisuride J Neural Transm 109 157 169
14. M Gomez-Vargas S Nishibayashi-Asanuma M Asanuma Y Kondo E Iwata N Ogawa 1998 Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain Brain Res 790 202 208
15. JB Gramsbergen G Leegsma-Vogt K Venema J Noraberg J Korf 2003 Quantitative on-line monitoring of hippocampus glucose and lactate metabolism in organotypic cultures using biosensor technology J Neurochem 85 399 408
16. L Had-Aissouni DB Re A Nieoullon L Kerkerian-Le Goff 2002 Importance of astrocytic inactivation of synaptically released glutamate for cell survival in the central nervous system - are astrocytes vulnerable to low intracellular glutamate concentrations? J Physiol Paris 96 317 322
17. Y Huang L Cheung D Rowe G Halliday 2004 Genetic contributions to Parkinson's disease Brain Res Brain Res Rev 46 44 70
18. RM Hollingworth KI Ahammadsahib G Gadelhak JL [tmp] McLaughlin 1994 New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticides Biochem Soc Trans 22 230 233
19. SO Jacobsson CJ Fowler 1999 Dopamine and glutamate neurotoxicity in cultured chick telencephalic cells: effects of NMDA antagonists, antioxidants and MAO inhibitors Neurochem Int 34 49 62
20. P Jenner 2003 Oxidative stress in Parkinson's disease Ann Neurol 53 Suppl 3 26 36
21. Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P (2002) Free radicals in Parkinson's disease. J Neurol 249 (Suppl 2): II 01-05
22. S Kuzuhara H Mori N Izumiyama M Yoshimura Y Ihara 1988 Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study Acta Neuropathol (Berl) 75 345 353
23. LP Liang YS Ho M Patel 2000 Mitochondrial superoxide production in kainate-induced hippocampal damage Neuroscience 101 563 570
24. I Miyazaki M Asanuma FJ Diaz-Corrales K Miyoshi N Ogawa 2004 Direct evidence for expression of dopamine receptors in astrocytes from basal ganglia Brain Res 1029 120 123
25. TH Murphy M Miyamoto A Sastre RL Schnaar JT Coyle 1989 Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress Neuron 2 1547 1558
26. A Oka MJ Belliveau PA Rosenberg JJ Volpe 1993 Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention J Neurosci 13 1441 1453
27. CW Olanow 2002 The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58 Suppl 1 S33 S41
28. M Patel BJ Day JD Crapo I Fridovich JO [tmp] McNamara 1996 Requirement for superoxide in excitotoxic cell death Neuron 16 345 355
29. Plaitakis A, Shashidharan P (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 247 (Suppl 2) II 25-35
30. MS Pollanen DW Dickson C Bergeron 1993 Pathology and biology of the Lewy body J Neuropathol Exp Neurol 52 183 191
31. MH Polymeropoulos JJ Higgins LI Golbe WG Johnson SE Ide G Di Iorio G Sanges ES Stenroos LT Pho AA Schaffer AM Lazzarini RL Nussbaum RC Duvoisin 1996 Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 Science 274 1197 1199
32. K Radad G Gille R Moldzio H Saito WD Rausch 2004a Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate Brain Res 1021 41 53
33. K Radad G Gille R Moldzio H Saito K Ishige WD Rausch 2004b Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP+-affected mesencephalic dopaminergic cells J Neural Transm 111 37 45
34. P Riederer H Reichmann B Janetzky J Sian KP Lesch KW Lange KL Double T Nagatsu M Gerlach 2001 Neural degeneration in Parkinson's disease Adv Neurol 86 125 136
35. MC Rodriguez JA Obeso CW Olanow 1998 Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection Ann Neurol 44 Suppl 1 S175 S188
36. KM Savolainen J Loikkanen J Naarala 1995 Amplification of glutamate-induced oxidative stress Toxicol Lett 82/83 399 405
37. T Shang S Kotamraju SV Kalivendi CJ Hillard B Kalyanaraman 2004 1-Methyl-4-phenylpyridinium-inuced apoptosis in cerebellar granule neurons is mediated by transferring receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide J Biol Chem 279 19099 19112
38. G Shanker M Aschner 2001 Identification and characterization of uptake systems for cystine and cysteine in cultured astrocytes and neurons: evidence for methylmercury-targeted disruption of astrocyte transport J Neurosci Res 66 998 1002
39. TB Sherer R Betarbet JT Greenamyre 2002 Environment, mitochondria and Parkinson's disease The Neuroscientist 8 192 197
40. S Tan D Schubert P Maher 2001 Oxytosis: a novel form of programmed cell death Curr Top Med Chem 1 497 506
41. R Tintner J Jankovic 2003 Dopamine agonists in Parkinson's disease Expert Opin Invest Drugs 12 1803 1820
42. MJ Tsai EHY Lee 1998 Nitric oxide donors protect cultured rat astrocytes from 1-methyl-4-phenylpyridinium-induced toxicity Free Radic Biol Med 24 705 713
43. S Vesce L Kirk DG Nicholls 2004 Relationship between superoxide levels and delayed calcium deregulation in cultured cerebellar granule cells exposed continuously to glutamate J Neurochem 90 683 693
44. SS Wong RHY Li A Stadlin 1999 Oxidative stress induced by MPTP and MPP+: selective vulnerability of cultured mouse astrocytes Brain Res 836 237 244
45. M Yoshioka K Tanaka I Miyazaki N Fujita Y Higashi M Asanuma N Ogawa 2002 The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals Neurosci Res 43 259 267
46. BT Zhu 2004 CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease Int J Mol Med 13 343 353